...
机译:靶向疗法在转移肾细胞癌中PD-1 / PD-L1阻断后的疗效
Harvard Univ Sch Med Brigham &
Womens Hosp Dana Farber Canc Inst Kidney Canc Ctr Boston MA;
Harvard Univ Sch Med Brigham &
Womens Hosp Dana Farber Canc Inst Kidney Canc Ctr Boston MA;
Harvard Univ Sch Med Brigham &
Womens Hosp Dana Farber Canc Inst Kidney Canc Ctr Boston MA;
Harvard Univ Sch Med Brigham &
Womens Hosp Dana Farber Canc Inst Kidney Canc Ctr Boston MA;
Harvard Univ Sch Med Beth Israel Deaconess Med Ctr Boston MA 02215 USA;
Tom Baker Canc Clin Calgary AB Canada;
Univ Paris 11 Gustave Roussy Canc Campus Dept Canc Med Villejuif France;
Harvard Univ Sch Med Brigham &
Womens Hosp Dana Farber Canc Inst Kidney Canc Ctr Boston MA;
Harvard Univ Sch Med Brigham &
Womens Hosp Dana Farber Canc Inst Kidney Canc Ctr Boston MA;
Univ Paris 11 Gustave Roussy Canc Campus Dept Canc Med Villejuif France;
Harvard Univ Sch Med Brigham &
Womens Hosp Dana Farber Canc Inst Kidney Canc Ctr Boston MA;
Renal cell carcinoma; Targeted therapy; PD-1; PD-L1; VEGFR; mTOR;
机译:靶向疗法在转移肾细胞癌中PD-1 / PD-L1阻断后的疗效
机译:在因免疫相关不良事件而中断PD-1 / PD-L1治疗的转移性肾细胞癌患者中的持久临床益处
机译:在因免疫相关不良事件而中断PD-1 / PD-L1治疗的转移性肾细胞癌患者中的持久临床益处
机译:何时治疗转移性肾细胞癌的组合,全身治疗,以及在转移性肾癌中的活跃监测
机译:PD-L1特异性辅助性T细胞表现出有效的抗肿瘤反应:针对头颈部鳞状细胞癌中PD-L1的癌症免疫疗法的新策略。
机译:PD-L1和PD-1的可溶性形式是阳光尼菌患者转移性透明细胞肾细胞癌患者的预后和预测标志
机译:靶向PD-1 / PD-L1在治疗转移性肾细胞癌